Oxidative stress and redox signaling in CRPC progression: therapeutic potential of clinically-tested Nrf2-activators [0.03%]
氧化应激与CRPC进展中的红氧信号：临床试验激活Nrf2的治疗潜力
Debasis Mondal,Devin Narwani,Shahnawaz Notta et al.
Debasis Mondal et al.
Androgen deprivation therapy (ADT) is the mainstay regimen in patients with androgen-dependent prostate cancer (PCa). However, the selection of androgen-independent cancer cells leads to castrate resistant prostate cancer (CRPC). The aggres...
Approaches to identifying drug resistance mechanisms to clinically relevant treatments in childhood rhabdomyosarcoma [0.03%]
儿童横纹肌肉瘤临床相关治疗药物耐药机制鉴定方法学研究进展
Samson Ghilu,Christopher L Morton,Angelina V Vaseva et al.
Samson Ghilu et al.
Aim: Despite aggressive multiagent protocols, patients with metastatic rhabdomyosarcoma (RMS) have poor prognosis. In a recent high-risk trial (ARST0431), 25% of patients failed within the first year, while on therapy and...
Yuhao Wang,Emily Hays,Martina Rama et al.
Yuhao Wang et al.
The genetic and epigenetic aberrations that underlie immune resistance lead to tumors that are refractory to clinically established and experimental immunotherapies, including monoclonal antibodies and T cell-based therapies. From various f...
Overcoming drug resistance by targeting protein homeostasis in multiple myeloma [0.03%]
通过靶向蛋白稳态来克服骨髓瘤的药物耐药性
Maria Moscvin,Matthew Ho,Giada Bianchi
Maria Moscvin
Multiple myeloma (MM) is a plasma cell disorder typically characterized by abundant synthesis of clonal immunoglobulin or free light chains. Although incurable, a deeper understanding of MM pathobiology has fueled major therapeutical advanc...
The roles of the human ATP-binding cassette transporters P-glycoprotein and ABCG2 in multidrug resistance in cancer and at endogenous sites: future opportunities for structure-based drug design of inhibitors [0.03%]
人类ATP结合盒式转运蛋白P-糖蛋白和ABCG2在癌症和内源位点的多药耐药性中的作用：基于结构设计抑制剂的未来机遇
Jason Goebel,Jean Chmielewski,Christine A Hrycyna
Jason Goebel
The ATP-binding cassette (ABC) transporters P-glycoprotein (P-gp) and ABCG2 are multidrug transporters that confer drug resistance to numerous anti-cancer therapeutics in cell culture. These findings initially created great excitement in th...
Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat [0.03%]
博来霉素耐药的多发性骨髓瘤中组蛋白去乙酰化酶(HDAC)家族成员的表达及泛脱乙酰化药物对其的调节作用
Tiewei Cheng,Kendall Kiser,Leslie Grasse et al.
Tiewei Cheng et al.
Aim: Multiple myeloma (MM) is a hematological malignancy of antibody-producing mature B cells or plasma cells. The proteasome inhibitor, bortezomib, was the first-in-class compound to be FDA approved for MM and is frequen...
Research advances and new challenges in overcoming triple-negative breast cancer [0.03%]
三阴性乳腺癌治疗研究进展与新挑战
Yu Zong,Mark Pegram
Yu Zong
Triple-negative breast cancer (TNBC) is a pathological term used to identify invasive breast cancers that lack expression of estrogen and progesterone receptors and do not have pathologic overexpression of the HER2 receptor or harbor ERBB2 ...
Imaging methods to evaluate tumor microenvironment factors affecting nanoparticle drug delivery and antitumor response [0.03%]
评估影响纳米颗粒药物传递和抗肿瘤反应的肿瘤微环境因素的成像方法
Amber S Moody,Paul A Dayton,William C Zamboni
Amber S Moody
Standard small molecule and nanoparticulate chemotherapies are used for cancer treatment; however, their effectiveness remains highly variable. One reason for this variable response is hypothesized to be due to nonspecific drug distribution...
Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment [0.03%]
FGFR1驱动的白血病和淋巴瘤对FGFR1抑制剂产生抗性的机制及其对优化治疗的影响
John K Cowell,Tianxiang Hu
John K Cowell
Myeloid and lymphoid neoplasms with eosinophilia and FGFR1 rearrangements (MLN-eo FGFR1) disease is derived from a pluripotent hematopoietic stem cell and has a complex presentation with a myeloproliferative disorder with or without eosinop...